阿达木单抗高剂量与标准剂量诱导及维持方案治疗溃疡性结肠炎的比较:SERENE UC 试验结果
SERENE UC 是一项 3 期双盲随机试验,纳入 18-75 岁、全 Mayo 评分 6-12 分、中心判读内镜评分 2-3 分的溃疡性结肠炎患者。高剂量诱导方案(第 0、1、2、3 周各 160 mg)与标准诱导方案(第 0 周 160 mg、第 2 周 80 mg)第 8 周临床缓解率分别为 13.3% 与 10.9%(P = .265),主要终点未达到。在主要研究中,第 8 周应答者接受 40 mg 每周 vs 每两周维持治疗,第 52 周临床缓解率分别为 39.5% 与 29.0%(P = .069);在整合(主要+日本)人群中分别为 41.1% 与 30.1%(名义 P = .045)。安全性特征在各给药方案间相当。
要点
- 高剂量诱导方案第 8 周临床缓解率为 13.3%,标准诱导方案为 10.9%,差异未达统计学显著(P = .265)。
- 主要研究中 40 mg 每周 vs 每两周维持治疗第 52 周临床缓解率为 39.5% vs 29.0%,未达统计学显著(P = .069)。
- 整合人群中 40 mg 每周 vs 每两周第 52 周临床缓解率为 41.1% vs 30.1%(名义 P = .045)。
核心结论
- 虽然主要终点未达到,但高剂量阿达木单抗维持治疗在临床缓解上显示出大于 10% 的绝对差异。
- 高剂量方案总体耐受性良好,与阿达木单抗在溃疡性结肠炎中已知的安全性特征一致。
研究设计与样本
- SERENE UC 为 3 期双盲随机试验,包含诱导研究和维持研究,设主要研究(日本以外)和日本子研究。
- 纳入 18-75 岁、全 Mayo 评分 6-12 分、中心判读内镜评分 2-3 分的溃疡性结肠炎患者。
- 诱导期按 3:2 随机分配至高剂量诱导方案(第 0、1、2、3 周各 160 mg)或标准诱导方案(第 0 周 160 mg、第 2 周 80 mg),所有患者第 4、6 周接受 40 mg。
- 第 8 周时主要研究按 2:2:1 重新随机分配至 40 mg 每周、40 mg 每两周或探索性治疗药物监测;日本子研究按 1:1 重新随机分配至 40 mg 每周或 40 mg 每两周维持方案。
主要发现
- 主要研究中,高剂量诱导方案组 vs 标准诱导方案组第 8 周临床缓解(全 Mayo 评分 ≤2 且无单项评分 >1)率为 13.3% vs 10.9%(诱导主要终点,P = .265)。
- 主要研究中,第 8 周应答者接受 40 mg 每周 vs 40 mg 每两周维持治疗,第 52 周临床缓解率为 39.5% vs 29.0%(维持主要终点,P = .069)。
- 整合(主要+日本)人群中,第 8 周应答者接受 40 mg 每周 vs 40 mg 每两周维持治疗,第 52 周临床缓解率为 41.1% vs 30.1%(名义 P = .045)。
- 安全性特征在各给药方案间相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: SERENE UC (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Ulcerative Colitis) evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis. METHODS: This phase 3, double-blind, randomized trial included induction and maintenance studies, with a main study (ex-Japan) and Japan substudy. Eligible patients (18-75 years, full Mayo score 6-12, centrally read endoscopy subscore 2-3) were randomized 3:2 to higher induction regimen (adalimumab 160 mg at weeks 0, 1, 2, and 3) or standard induction regimen (160 mg at week 0 and 80 mg at week 2); all received 40 mg at weeks 4 and 6. At week 8, all patients were rerandomized 2:2:1 (main study) to 40 mg every week (ew), 40 mg every other week (eow), or exploratory therapeutic drug monitoring; or 1:1 (Japan substudy) to 40 mg ew or 40 mg eow maintenance regimens. RESULTS: In the main study, 13.3% vs 10.9% of patients receiving the higher induction regimen vs standard induction regimen achieved clinical remission (full Mayo score ≤2 with no subscore >1) at week 8 (induction primary end point; P = .265); among week-8 responders, 39.5% vs 29.0% receiving 40 mg ew vs 40 mg eow achieved clinical remission at week 52 (maintenance primary end point; P = .069). In the integrated (main + Japan) population, 41.1% vs 30.1% of week-8 responders receiving 40 mg ew vs 40 mg eow achieved clinical remission at week 52 (nominal P = .045). Safety profiles were comparable between dosing regimens. CONCLUSION: Although primary end points were not met, a >10% absolute difference in clinical remission was demonstrated with higher adalimumab maintenance dosing. Higher dosing regimens were generally well tolerated and consistent with the known safety profile of adalimumab in ulcerative colitis. CLINICALTRIALS: gov, Number: NCT002209456.
引用
- Panés J, Colombel JF, D'Haens GR, et al. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology. 2022. PMID: 35227777. doi:10.1053/j.gastro.2022.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。